KZN tackles medicine shortages through redistribution and therapeutic alternatives

When a patient arrives at a public clinic in KwaZulu-Natal needing epilepsy medication, the doctor may not have the drug on the shelf. This is not because the province failed to order it. It is because somewhere across an ocean, a factory that makes the pills has run out of a single ingredient—one of many that go into a single tablet—and the supply chain has broken.

The KwaZulu-Natal Department of Health is confronting a cascade of medicine shortages that ripple through its public healthcare system. Officials attribute the problem not to procurement failures but to disruptions in global supply chains. Epilepsy medications, tuberculosis drugs, and contraceptive pills have all become scarce in recent months. The shortages are real, but they are being managed through a combination of practical strategies: moving stock between hospitals and clinics, substituting one drug for another when medically sound, and waiting for suppliers to refill their warehouses.

Health MEC Nomagugu Simelane explained the mechanics of the problem in plain terms. A medicine is rarely a single substance. It is a compound of many ingredients sourced from different places—some manufactured locally, others ordered from overseas suppliers. When one ingredient runs out at a factory, production stops. When a supplier's shipment is delayed by geopolitical tensions or logistics failures, the entire chain stalls. "Sometimes, when we want the medicine or pill, it turns out that the manufacturer doesn't have it," Simelane said. The province did not stop buying. The suppliers simply stopped having stock to sell.

Thandeka Njapha, who manages the Provincial Pharmaceutical Supply Depot, confirmed that KZN is not uniquely affected. The shortage of Phenobarbital, an epilepsy medication, is not a provincial problem but a national one. A circular from the National Department of Health was issued to acknowledge it. Rifampicin, used to treat tuberculosis, faces similar constraints. Certain contraceptive pills are also in short supply. Yet Njapha emphasized that the department has not abandoned patients. When Phenobarbital is unavailable, doctors and nurses have identified alternative medications that can achieve the same therapeutic result. If one contraceptive pill is scarce, others remain available, along with injections and implants. "We won't just let you go like that," Njapha said.

The response has been pragmatic. The department redistributes medicines between facilities, borrowing from hospitals with surplus stock to supply clinics in need. It has even coordinated across provincial borders, sharing supplies with other provinces facing identical pressures. Where possible, officials have sourced medicines from alternate suppliers rather than waiting for the primary vendor to restock. These are stopgap measures, not solutions, but they have kept the system functioning.

The underlying cause remains beyond the province's control. Wars in distant parts of the world delay shipments. Manufacturing delays compound. A single missing ingredient can halt production of a drug that thousands of patients depend on. Njapha acknowledged this bluntly: "The issues with transport and importing medicines from overseas, since there are wars in the world, affect us because there are delays."

Suppliers have promised that stock will normalize by July. Most have committed to restocking by then. Some medicines have already been sourced from alternative suppliers, reducing the wait. But the fragility of the system remains exposed. As long as medicines are manufactured far from where they are needed, and as long as global logistics remain unstable, shortages will recur. For now, KwaZulu-Natal is managing the gap between supply and need through redistribution, substitution, and the careful coordination of its health officials. The question is whether these measures will hold when the next disruption arrives.